Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.09)
# 365
Out of 4,810 analysts
230
Total ratings
40.91%
Success rate
14.05%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $3.02 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $14.99 | +86.79% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $102.91 | +45.76% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $103.83 | +47.36% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $8.99 | +55.73% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $32.41 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $18.56 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $7.75 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $28.75 | +101.74% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $27.94 | +53.90% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $38.56 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.59 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $96.16 | +61.19% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.95 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $13.17 | +165.76% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.37 | +197.48% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.70 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.38 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.60 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.39 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $23.23 | +46.36% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $29.66 | +68.58% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $2.70 | +85.19% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.36 | +1,025.49% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.13 | +253.98% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $33.03 | +75.60% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $0.82 | +13,296.66% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $3.07 | +2,505.86% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.06 | +183.02% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $9.12 | +20.61% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $5.25 | +128.57% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.39 | +2,529.11% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.23 | +796.86% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $18.58 | +976.43% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.29 | +1,296.65% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $1.43 | +1,578.32% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.76 | +8,081.82% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.25 | +220.00% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $408 → $480 | $5.32 | +8,922.56% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $61.28 | -36.36% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $69.59 | -78.45% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.74 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $4.53 | +3,873.51% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.02
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $14.99
Upside: +86.79%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $102.91
Upside: +45.76%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $103.83
Upside: +47.36%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $8.99
Upside: +55.73%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $32.41
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.56
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.75
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $28.75
Upside: +101.74%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $27.94
Upside: +53.90%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.56
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.59
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $96.16
Upside: +61.19%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.95
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $13.17
Upside: +165.76%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.37
Upside: +197.48%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.70
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.38
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.60
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.39
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $23.23
Upside: +46.36%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $29.66
Upside: +68.58%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $2.70
Upside: +85.19%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.36
Upside: +1,025.49%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.13
Upside: +253.98%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $33.03
Upside: +75.60%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $0.82
Upside: +13,296.66%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $3.07
Upside: +2,505.86%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.06
Upside: +183.02%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $9.12
Upside: +20.61%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $5.25
Upside: +128.57%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.39
Upside: +2,529.11%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.23
Upside: +796.86%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $18.58
Upside: +976.43%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.29
Upside: +1,296.65%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $1.43
Upside: +1,578.32%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.76
Upside: +8,081.82%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.25
Upside: +220.00%
May 19, 2020
Reiterates: Overweight
Price Target: $408 → $480
Current: $5.32
Upside: +8,922.56%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $61.28
Upside: -36.36%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $69.59
Upside: -78.45%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.74
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $4.53
Upside: +3,873.51%